Bayesian Capital Management, LP Repligen Corp Transaction History

Bayesian Capital Management, LP

$582 Million
Q1 2025

A detailed history of Bayesian Capital Management, LP transactions in Repligen Corp stock. As of the latest transaction made, Bayesian Capital Management, LP holds 2,066 shares of RGEN stock, worth $263,353. This represents 0.05% of its overall portfolio holdings.

Number of Shares

2,066

Previous 6,578 68.59%

Holding current value

$263,353

Previous $946,000 72.3%

% of portfolio

0.05%

Previous 0.12%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$127.24 - $174.24 $574,106 - $786,170	-4,512 Reduced 68.59%	2,066 $262,000
Q4 2024 Feb 14, 2025	BUY	$123.41 - $160.92 $811,790 - $1.06 Million	6,578 New	6,578 $946,000
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $279,737 - $341,391	1,638 Added 140.96%	2,800 $514,000
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $132,665 - $215,376	1,162 New	1,162 $208,000
Q1 2023 May 15, 2023	BUY	$154.26 - $198.1 $87,465 - $112,322	567 Added 11.4%	5,542 $933,000
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $808,039 - $1.1 Million	4,975 New	4,975 $842,000
Q1 2022 May 16, 2022	SELL	$161.19 - $257.96 $142,814 - $228,552	-886 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $219,364 - $269,760	886 New	886 $235,000
Q2 2021 Aug 13, 2021	SELL	$165.87 - $220.95 $497,610 - $662,850	-3,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$180.37 - $226.26 $378,777 - $475,146	-2,100 Reduced 41.18%	3,000 $583,000
Q4 2020 Feb 12, 2021	BUY	$148.08 - $206.57 $755,208 - $1.05 Million	5,100 New	5,100 $977,000
Q2 2018 Aug 14, 2018	SELL	$35.26 - $47.04 $222,596 - $296,963	-6,313 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$30.92 - $37.27 $195,197 - $235,285	6,313 New	6,313 $228,000

Others Institutions Holding RGEN

# of Institutions

495

Shares Held

57.6M

Call Options Held

75.6K

Put Options Held

521K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.07B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Account

Bayesian Capital Management, LP Repligen Corp Transaction History